Effect of Vitamin D Supplementation on Metabolic Parameters of Patients With Psoriasis

Effect of Vitamin D Supplementation on Metabolic Parameters of Patients With Moderate to Severe Psoriasis

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02271971

Enrollment

Registered

2014-10-22

Start date

2014-10-31

Completion date

2015-10-31

Last updated

2015-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome, Psoriasis, Vitamin D Deficiency

Keywords

Psoriasis, Vitamin D, Metabolic syndrome, Insulin resistance, Cholesterol, Methotrexate, Dyslipidemia, PASI, Psoriasis Area Severity Index

Brief summary

The purpose of this study is to determine whether supplementation with oral vitamin D (cholecalciferol) improves metabolic parameters in patients with moderate to severe psoriasis.

Interventions

DIETARY_SUPPLEMENTVitamin D3

A daily 5.000 IU vitamin D3 capsule during 6 weeks.

DIETARY_SUPPLEMENTPlacebo

A daily placebo capsule during 6 weeks.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of moderate to severe psoriasis. * Being treated with methotrexate with stable doses for al least 1 month.

Exclusion criteria

* Phototherapy within the past 2 months. * History of psoriatic arthritis, rheumatoid arthritis, type 1 diabetes mellitus or inflammatory bowel disease. * Use of vitamin d supplements or fish oil supplements in the past 2 months. * Use of hypolipidemic drugs, hypoglycemic drugs, glucose sensitizers, oral corticosteroids, orlistat, cholestyramine, phenobarbital or phenytoin within the past 2 months. * Pregnancy or lactation.

Design outcomes

Primary

Measure	Time frame
Change in Total Cholesterol Levels	Baseline and 6 weeks

Secondary

Measure	Time frame
Change in Fasting Glucose Levels	Baseline and 6 weeks
Change in HOMA Index	Baseline and 6 weeks
Change in Glycated Hemoglobin Levels	Baseline and 6 weeks
Change in Low-Density Lipoprotein Levels	Baseline and 6 weeks
Change in High-Density Lipoprotein Levels	Baseline and 6 weeks
Change in Triglycerides Levels	Baseline and 6 weeks
Change in C-Reactive Protein Levels	Baseline and 6 weeks
Change in Vitamin D Levels	Baseline and 6 weeks
Change in PASI (Psoriasis Area Severity Index)	Baseline and 6 weeks

Other

Measure	Time frame
Number of Participants with Adverse Events	Baseline and 6 weeks

Countries

Chile

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026